Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Depreciation and Depletion (2021 - 2025)

Historic Depreciation and Depletion for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $200000.0.

  • Aligos Therapeutics' Depreciation and Depletion fell 3333.33% to $200000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $927000.0, marking a year-over-year decrease of 2869.23%. This contributed to the annual value of $1.0 million for FY2024, which is 3581.25% down from last year.
  • According to the latest figures from Q3 2025, Aligos Therapeutics' Depreciation and Depletion is $200000.0, which was down 3333.33% from $300000.0 recorded in Q2 2025.
  • Over the past 5 years, Aligos Therapeutics' Depreciation and Depletion peaked at $800000.0 during Q2 2021, and registered a low of $200000.0 during Q1 2025.
  • Its 5-year average for Depreciation and Depletion is $462789.5, with a median of $400000.0 in 2023.
  • Examining YoY changes over the last 5 years, Aligos Therapeutics' Depreciation and Depletion showed a top increase of 0.0% in 2024 and a maximum decrease of 4325.0% in 2024.
  • Quarter analysis of 5 years shows Aligos Therapeutics' Depreciation and Depletion stood at $719000.0 in 2021, then decreased by 29.62% to $506000.0 in 2022, then decreased by 20.95% to $400000.0 in 2023, then tumbled by 43.25% to $227000.0 in 2024, then decreased by 11.89% to $200000.0 in 2025.
  • Its Depreciation and Depletion stands at $200000.0 for Q3 2025, versus $300000.0 for Q2 2025 and $200000.0 for Q1 2025.